Hippocampal and Clinical Trajectories of Mild Cognitive Impairment with Suspected Non-Alzheimer's Disease Pathology

Jun Ku Chung, Eric Plitman, Shinichiro Nakajima, Fernando Caravaggio, Yusuke Iwata, Philip Gerretsen, Julia Kim, Hiroyoshi Takeuchi, Shunichiro Shinagawa, Raihaan Patel, M. Mallar Chakravarty, Ariel Graff-Guerrero

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Suspected non-Alzheimer's disease pathology (SNAP) characterizes individuals showing neurodegeneration (e.g., hypometabolism) without amyloid-β (Aβ). Findings from previous studies regarding clinical and structural trajectories of SNAP are inconsistent. Using data from the Alzheimer's Disease Neuroimaging Initiative, patients with amnestic mild cognitive impairment (MCI) were categorized into four groups: amyloid positive with hypometabolism (AβND), amyloid only (AβND-), neither amyloid nor hypometabolism (Aβ-ND-), and SNAP (Aβ-ND). AβND(n=33), AβND-(n=32), and Aβ-ND-(n=36) were matched to SNAP for age, gender, apolipoprotein E4 (apoE4) genotype, and scores on the Montreal Cognitive Assessment. Elderly controls (n=40) were also matched to SNAP for age, gender, and apoE4 genotype. Longitudinal changes were compared across groups in terms of hippocampal volume, clinical symptoms, daily functioning, and cognitive functioning over a 2-year period. At baseline, no difference in cognition and functioning was observed between SNAP and Aβgroups. SNAP showed worse clinical symptoms and impaired functioning at baseline compared to Aβ-ND-and controls. Two years of follow-up showed no differences in hippocampal volume changes between SNAP and any of the comparison groups. SNAP showed worse functional deterioration in comparison to Aβ-ND-and controls. However, AβND showed more severe changes in clinical symptoms in comparison to SNAP. Thus, patients with MCI and SNAP showed 1) more severe functional deterioration compared to Aβ-ND-and controls, 2) no differences with AβND-, and 3) less cognitive deterioration than AβND. Future studies should investigate what causes SNAP, which is different from typical AD pathology and biomarker cascades.

Original languageEnglish
Pages (from-to)747-762
Number of pages16
JournalJournal of Alzheimer's Disease
Volume58
Issue number3
DOIs
Publication statusPublished - 2017

Fingerprint

Pathology
Amyloid
Apolipoprotein E4
Cognitive Dysfunction
Genotype
Neuroimaging
Cognition
Alzheimer Disease
Biomarkers

Keywords

  • Functional decline
  • hippocampus
  • mild cognitive impairment
  • suspected non-Alzheimer's pathology

ASJC Scopus subject areas

  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Hippocampal and Clinical Trajectories of Mild Cognitive Impairment with Suspected Non-Alzheimer's Disease Pathology. / Chung, Jun Ku; Plitman, Eric; Nakajima, Shinichiro; Caravaggio, Fernando; Iwata, Yusuke; Gerretsen, Philip; Kim, Julia; Takeuchi, Hiroyoshi; Shinagawa, Shunichiro; Patel, Raihaan; Chakravarty, M. Mallar; Graff-Guerrero, Ariel.

In: Journal of Alzheimer's Disease, Vol. 58, No. 3, 2017, p. 747-762.

Research output: Contribution to journalArticle

Chung, JK, Plitman, E, Nakajima, S, Caravaggio, F, Iwata, Y, Gerretsen, P, Kim, J, Takeuchi, H, Shinagawa, S, Patel, R, Chakravarty, MM & Graff-Guerrero, A 2017, 'Hippocampal and Clinical Trajectories of Mild Cognitive Impairment with Suspected Non-Alzheimer's Disease Pathology', Journal of Alzheimer's Disease, vol. 58, no. 3, pp. 747-762. https://doi.org/10.3233/JAD-170201
Chung, Jun Ku ; Plitman, Eric ; Nakajima, Shinichiro ; Caravaggio, Fernando ; Iwata, Yusuke ; Gerretsen, Philip ; Kim, Julia ; Takeuchi, Hiroyoshi ; Shinagawa, Shunichiro ; Patel, Raihaan ; Chakravarty, M. Mallar ; Graff-Guerrero, Ariel. / Hippocampal and Clinical Trajectories of Mild Cognitive Impairment with Suspected Non-Alzheimer's Disease Pathology. In: Journal of Alzheimer's Disease. 2017 ; Vol. 58, No. 3. pp. 747-762.
@article{955ff4e51b594174b822c83c3772df94,
title = "Hippocampal and Clinical Trajectories of Mild Cognitive Impairment with Suspected Non-Alzheimer's Disease Pathology",
abstract = "Suspected non-Alzheimer's disease pathology (SNAP) characterizes individuals showing neurodegeneration (e.g., hypometabolism) without amyloid-β (Aβ). Findings from previous studies regarding clinical and structural trajectories of SNAP are inconsistent. Using data from the Alzheimer's Disease Neuroimaging Initiative, patients with amnestic mild cognitive impairment (MCI) were categorized into four groups: amyloid positive with hypometabolism (AβND), amyloid only (AβND-), neither amyloid nor hypometabolism (Aβ-ND-), and SNAP (Aβ-ND). AβND(n=33), AβND-(n=32), and Aβ-ND-(n=36) were matched to SNAP for age, gender, apolipoprotein E4 (apoE4) genotype, and scores on the Montreal Cognitive Assessment. Elderly controls (n=40) were also matched to SNAP for age, gender, and apoE4 genotype. Longitudinal changes were compared across groups in terms of hippocampal volume, clinical symptoms, daily functioning, and cognitive functioning over a 2-year period. At baseline, no difference in cognition and functioning was observed between SNAP and Aβgroups. SNAP showed worse clinical symptoms and impaired functioning at baseline compared to Aβ-ND-and controls. Two years of follow-up showed no differences in hippocampal volume changes between SNAP and any of the comparison groups. SNAP showed worse functional deterioration in comparison to Aβ-ND-and controls. However, AβND showed more severe changes in clinical symptoms in comparison to SNAP. Thus, patients with MCI and SNAP showed 1) more severe functional deterioration compared to Aβ-ND-and controls, 2) no differences with AβND-, and 3) less cognitive deterioration than AβND. Future studies should investigate what causes SNAP, which is different from typical AD pathology and biomarker cascades.",
keywords = "Functional decline, hippocampus, mild cognitive impairment, suspected non-Alzheimer's pathology",
author = "Chung, {Jun Ku} and Eric Plitman and Shinichiro Nakajima and Fernando Caravaggio and Yusuke Iwata and Philip Gerretsen and Julia Kim and Hiroyoshi Takeuchi and Shunichiro Shinagawa and Raihaan Patel and Chakravarty, {M. Mallar} and Ariel Graff-Guerrero",
year = "2017",
doi = "10.3233/JAD-170201",
language = "English",
volume = "58",
pages = "747--762",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "3",

}

TY - JOUR

T1 - Hippocampal and Clinical Trajectories of Mild Cognitive Impairment with Suspected Non-Alzheimer's Disease Pathology

AU - Chung, Jun Ku

AU - Plitman, Eric

AU - Nakajima, Shinichiro

AU - Caravaggio, Fernando

AU - Iwata, Yusuke

AU - Gerretsen, Philip

AU - Kim, Julia

AU - Takeuchi, Hiroyoshi

AU - Shinagawa, Shunichiro

AU - Patel, Raihaan

AU - Chakravarty, M. Mallar

AU - Graff-Guerrero, Ariel

PY - 2017

Y1 - 2017

N2 - Suspected non-Alzheimer's disease pathology (SNAP) characterizes individuals showing neurodegeneration (e.g., hypometabolism) without amyloid-β (Aβ). Findings from previous studies regarding clinical and structural trajectories of SNAP are inconsistent. Using data from the Alzheimer's Disease Neuroimaging Initiative, patients with amnestic mild cognitive impairment (MCI) were categorized into four groups: amyloid positive with hypometabolism (AβND), amyloid only (AβND-), neither amyloid nor hypometabolism (Aβ-ND-), and SNAP (Aβ-ND). AβND(n=33), AβND-(n=32), and Aβ-ND-(n=36) were matched to SNAP for age, gender, apolipoprotein E4 (apoE4) genotype, and scores on the Montreal Cognitive Assessment. Elderly controls (n=40) were also matched to SNAP for age, gender, and apoE4 genotype. Longitudinal changes were compared across groups in terms of hippocampal volume, clinical symptoms, daily functioning, and cognitive functioning over a 2-year period. At baseline, no difference in cognition and functioning was observed between SNAP and Aβgroups. SNAP showed worse clinical symptoms and impaired functioning at baseline compared to Aβ-ND-and controls. Two years of follow-up showed no differences in hippocampal volume changes between SNAP and any of the comparison groups. SNAP showed worse functional deterioration in comparison to Aβ-ND-and controls. However, AβND showed more severe changes in clinical symptoms in comparison to SNAP. Thus, patients with MCI and SNAP showed 1) more severe functional deterioration compared to Aβ-ND-and controls, 2) no differences with AβND-, and 3) less cognitive deterioration than AβND. Future studies should investigate what causes SNAP, which is different from typical AD pathology and biomarker cascades.

AB - Suspected non-Alzheimer's disease pathology (SNAP) characterizes individuals showing neurodegeneration (e.g., hypometabolism) without amyloid-β (Aβ). Findings from previous studies regarding clinical and structural trajectories of SNAP are inconsistent. Using data from the Alzheimer's Disease Neuroimaging Initiative, patients with amnestic mild cognitive impairment (MCI) were categorized into four groups: amyloid positive with hypometabolism (AβND), amyloid only (AβND-), neither amyloid nor hypometabolism (Aβ-ND-), and SNAP (Aβ-ND). AβND(n=33), AβND-(n=32), and Aβ-ND-(n=36) were matched to SNAP for age, gender, apolipoprotein E4 (apoE4) genotype, and scores on the Montreal Cognitive Assessment. Elderly controls (n=40) were also matched to SNAP for age, gender, and apoE4 genotype. Longitudinal changes were compared across groups in terms of hippocampal volume, clinical symptoms, daily functioning, and cognitive functioning over a 2-year period. At baseline, no difference in cognition and functioning was observed between SNAP and Aβgroups. SNAP showed worse clinical symptoms and impaired functioning at baseline compared to Aβ-ND-and controls. Two years of follow-up showed no differences in hippocampal volume changes between SNAP and any of the comparison groups. SNAP showed worse functional deterioration in comparison to Aβ-ND-and controls. However, AβND showed more severe changes in clinical symptoms in comparison to SNAP. Thus, patients with MCI and SNAP showed 1) more severe functional deterioration compared to Aβ-ND-and controls, 2) no differences with AβND-, and 3) less cognitive deterioration than AβND. Future studies should investigate what causes SNAP, which is different from typical AD pathology and biomarker cascades.

KW - Functional decline

KW - hippocampus

KW - mild cognitive impairment

KW - suspected non-Alzheimer's pathology

UR - http://www.scopus.com/inward/record.url?scp=85020378070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020378070&partnerID=8YFLogxK

U2 - 10.3233/JAD-170201

DO - 10.3233/JAD-170201

M3 - Article

VL - 58

SP - 747

EP - 762

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 3

ER -